Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients
Year: 2020
Type: article
Source: Blood
Authors: John Mascarenhas, Rami S. Komrokji, Michele Cavo, Bruno Martino, Dietger Niederwieser, Andreas Reiter, Bart L. Scott, Maria R. Baer, Ronald Hoffman, Olatoyosi Odenike, Laurie Sherman, Souria Dougherty, Faye Feller, Tymara Berry, Libo Sun, Ying Wan, Aleksandra Rizo, Fei Huang, Jean-Jacques Kiladjian
Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Moffitt Cancer Center, University of Bologna, Azienda ospedaliera "Bianchi-Melacrino-Morelli", University Hospital Leipzig, Heidelberg University, Fred Hutch Cancer Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Chicago, Geron (United States), Université Paris Cité, Hôpital Saint-Louis
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3095897988